| The Dual Pandemics of COVID-19 and Obesity: Bidirectional Impact | Diabetes Therapy | 6 days | save |  |  |  |
| The Case for Early and Universal Screening for Gestational Diabetes Mellitus: Findings from 9314 Pregnant Women in a Major City in Nigeria | Diabetes Therapy | 6 days | save | | | |
| Diabetes Therapy Podcast: Mind–Body Medicine in Diabetes Management | Diabetes Therapy | 6 days | save | | | |
| Real-World Treatment Patterns of Glucose-Lowering Agents Among Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease or At Risk for Cardiovascular Disease: An Observational, Cross-Sectional, Retrospective Study | Diabetes Therapy | 7 days | save | | | |
| Astragaloside IV Regulates Insulin Resistance and Inflammatory Response of Adipocytes via Modulating CTRP3 and PI3K/AKT Signaling | Diabetes Therapy | 14 days | save | | | |
| Continuous Glucose Monitoring System Profile of Women with Gestational Diabetes Mellitus Missed Using Isolated Fasting Plasma Glucose-Based Strategies Alternative to WHO 2013 Criteria: A Cross-Sectional Study | Diabetes Therapy | 14 days | save | | | |
| Barriers and Facilitators to the Initiation of Injectable Therapies for Type 2 Diabetes Mellitus: A Mixed Methods Study | Diabetes Therapy | 26 days | save | | | |
| Diabetic Mononeuropathies and Diabetic Amyotrophy | Diabetes Therapy | 44 days | save | | | |
| Association of Time in Range with Endothelial Injury in Patients with Type 2 Diabetes Treated with Exenatide | Diabetes Therapy | 45 days | save | | | |
| Long-Term Cost-Effectiveness Analysis of Once-Weekly Semaglutide versus Dulaglutide in Patients with Type 2 Diabetes with Inadequate Glycemic Control in China | Diabetes Therapy | 51 days | save | | | |
| A Response to: Letter to the Editor regarding“Importance of Early Screening and Diagnosis of Chronic Kidney Disease in Patients with Type 2 Diabetes” | Diabetes Therapy | 53 days | save | | | |
| Letter to the Editor Regarding“Importance of Early Screening and Diagnosis of Chronic Kidney Disease in Patients with Type 2 Diabetes” | Diabetes Therapy | 53 days | save | | | |
| Cost-Effectiveness of iGlarLixi Versus Premix BIAsp 30 in People with Type 2 Diabetes Suboptimally Controlled by Basal Insulin in the US | Diabetes Therapy | 54 days | save | | | |
| Comparison Between Continuous Versus Flash Glucose Monitoring in Children, Adolescents, and Young Adults with Type 1 Diabetes: An 8-Week Prospective Randomized Trial | Diabetes Therapy | 67 days | save | | | |
| Clinical Benefit of Switching from Low-Dose to High-Dose Empagliflozin in Patients with Type 2 Diabetes | Diabetes Therapy | 74 days | save | | | |
| Impact of Partial Meal Replacement on Glycemic Levels and Body Weight in Indian Patients with Type 2 Diabetes (PRIDE): A Randomized Controlled Study | Diabetes Therapy | 76 days | save | | | |
| Distress and Living with Diabetes: Defining Characteristics Through an Online Survey | Diabetes Therapy | 76 days | save | | | |
| Prediabetes in Syria and Its Associated Factors: A Single-Center Cross-Sectional Study | Diabetes Therapy | 77 days | save | | | |
| Comparison of the Effectiveness of Once-Daily Alogliptin/Metformin and Twice-Daily Anagliptin/Metformin Combination Tablet in a Randomized, Parallel-Group, Open-Label Trial in Japanese Patients with Type 2 Diabetes | Diabetes Therapy | 84 days | save | | | |
| Efficacy and Safety of Ultra-Rapid Lispro in Younger and Older Patients with Type 2 Diabetes: Randomized Double-Blind PRONTO-T2D Study | Diabetes Therapy | 86 days | save | | | |
| Correction to: The FIDELIO Study Podcast | Diabetes Therapy | 87 days | save | | | |
| Association Between the Tissue and Circulating Advanced Glycation End-Products and the Micro- and Macrovascular Complications in Type 1 Diabetes: The DIABAGE Study | Diabetes Therapy | 88 days | save | | | |
| IDegLira for the Real-World Treatment of Type 2 Diabetes in Italy: Protocol and Interim Results from the REX Observational Study | Diabetes Therapy | 101 days | save | | | |
| Efficacy and Safety of Insulin Glargine 300 U/mL in People with Type 2 Diabetes Uncontrolled on Basal Insulin: The 26-Week Interventional, Single-Arm ARTEMIS-DM Study | Diabetes Therapy | 102 days | save | | | |
| A Pilot Study to Assess Glucose, Insulin, and Incretin Responses Following Novel High Resistant Starch Rice Ingestion in Healthy Men | Diabetes Therapy | 103 days | save | | | |
| Cost-Effectiveness Analysis of Initiating Type 2 Diabetes Therapy with a Sodium–Glucose Cotransporter 2 Inhibitor Versus Conventional Therapy in Japan | Diabetes Therapy | 103 days | save | | | |
| SGLT2 Inhibitors and the Cardiorenal Continuum: A Paradigm Shift in the Treatment of Patients with T2D | Diabetes Therapy | 104 days | save | | | |
| Review of SGLT2i for the Treatment of Renal Complications: Experience in Patients with and Without T2D | Diabetes Therapy | 104 days | save | | | |
| Prevention of Cardiorenal Complications with Sodium–Glucose Cotransporter Type 2 Inhibitors: A Narrative Review | Diabetes Therapy | 104 days | save | | | |
| Benefits of SGLT2i for the Treatment of Heart Failure Irrespective of Diabetes Diagnosis: A State-of-the-Art Review | Diabetes Therapy | 104 days | save | | | |
| Blood Glucose Fluctuation in Older Adults with Diabetes Mellitus and End-Stage Renal Disease on Maintenance Hemodialysis: An Observational Study | Diabetes Therapy | 108 days | save | | | |
| Characteristics and Treatment Patterns of Patients with Type 2 Diabetes Mellitus in the Middle East and Africa Cohort of the DISCOVER Study Program: a Prospective Study | Diabetes Therapy | 108 days | save | | | |
| Beyond the Glycaemic Control of Dapagliflozin: Impact on Arterial Stiffness and Macroangiopathy | Diabetes Therapy | 109 days | save | | | |
| Management of Diabetes and Hypertension within the Gulf Region: Updates on Treatment Practices and Therapies | Diabetes Therapy | 110 days | save | | | |
| Glycaemic Control Achieves Sustained Increases of Circulating Endothelial Progenitor Cells in Patients Hospitalized for Decompensated Diabetes: An Observational Study | Diabetes Therapy | 111 days | save | | | |
| Efficacy, Safety, and Immunogenicity of Biosimilar Insulin Aspart Premix SAR341402 Mix 70/30 Compared with Originator Insulin Aspart Mix 70/30 in Adults with Diabetes (GEMELLI M): A Subgroup Analysis by Prior Type of Premix Insulin | Diabetes Therapy | 118 days | save | | | |
| Exercise Intervention as a Therapy in Patients with Diabetes Mellitus and Sarcopenia: A Meta-Analysis | Diabetes Therapy | 118 days | save | | | |
| Study Design and Baseline Characteristics of Patients with T2DM in the Post-marketing Safety Study of Dulaglutide in China (TRUST-CHN) | Diabetes Therapy | 133 days | save | | | |
| Bioequivalence Studies of New Generic Formulations of Vildagliptin and Fixed-Drug Combination of Vildagliptin and Metformin Versus Respective Originator Products in Healthy Volunteers | Diabetes Therapy | 140 days | save | | | |
| Cost-Effectiveness of iGlarLixi Versus Premix BIAsp 30 in Patients with Type 2 Diabetes Suboptimally Controlled by Basal Insulin in the UK | Diabetes Therapy | 140 days | save | | | |
| Real-World Effectiveness and Safety of Insulin Glargine 300 U/mL in Insulin-Naïve People with Type 2 Diabetes: the ATOS Study | Diabetes Therapy | 142 days | save | | | |
| Oral Semaglutide: Dosage in Special Situations | Diabetes Therapy | 142 days | save | | | |
| Reductions in HbA1c with Flash Glucose Monitoring Are Sustained for up to 24 Months: A Meta-Analysis of 75 Real-World Observational Studies | Diabetes Therapy | 154 days | save | | | |
| Efficacy and Safety of LY2963016 Insulin Glargine in Chinese Patients with Type 1 Diabetes Previously Treated with Insulin Glargine (Lantus®): a Post Hoc Analysis of a Randomized, Open-Label, Phase 3 Trial | Diabetes Therapy | 154 days | save | | | |
| Correction to: Effectiveness in Real World of Once Weekly Semaglutide in People with Type 2 Diabetes: Glucagon-Like Peptide Receptor Agonist Naïve or Switchers from Other Glucagon-Like Peptide Receptor Agonists: Results from a Retrospective Observati | Diabetes Therapy | 157 days | save | | | |
| Acute Administration of the GLP-1 Receptor Agonist Lixisenatide Diminishes Postprandial Insulin Secretion in Healthy Subjects But Not in Type 2 Diabetes, Associated with Slowing of Gastric Emptying | Diabetes Therapy | 158 days | save | | | |
| Profile of Patients with Diabetes Treated with Insulin Lispro 200 U/ml: A Real-World Study from Spain | Diabetes Therapy | 159 days | save | | | |
| Measuring the Impact of Flash Glucose Monitoring in a Pediatric Population in Saudi Arabia: A Retrospective Cohort Study | Diabetes Therapy | 161 days | save | | | |
| Observational Study on Unhealthy Eating Behavior and the Effect of Sodium-Glucose Cotransporter 2 Inhibitors: The Luseogliflozin Ehime Diabetes Study | Diabetes Therapy | 166 days | save | | | |
| Biosimilar Insulin Aspart Premix SAR341402 Mix 70/30 Versus Originator Insulin Aspart Mix 70/30 (NovoMix 30) in People with Diabetes: A 26-Week, Randomized, Open-Label Trial (GEMELLI M) | Diabetes Therapy | 167 days | save | | | |
| | 
report | next » |
| |
